



# Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text<sup>†</sup>

## The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

**Authors/Task Force Members, Lars Rydén, Co-Chairperson (Sweden)\*, Eberhard Standl, Co-Chairperson (Germany)\*, Małgorzata Bartnik (Poland), Greet Van den Berghe (Belgium), John Betteridge (UK), Menko-Jan de Boer (The Netherlands), Francesco Cosentino (Italy), Bengt Jönsson (Sweden), Markku Laakso (Finland), Klas Malmberg (Sweden), Silvia Priori (Italy), Jan Östergren (Sweden), Jaakko Tuomilehto (Finland), Inga Thrainsdottir (Iceland)**

**Other Contributors, Ilse Vanhorebeek (Belgium), Marco Stramba-Badiale (Italy), Peter Lindgren (Sweden) Qing Qiao (Finland)**


**ESC Committee for Practice Guidelines (CPG), Silvia G. Priori, Chairperson (Italy), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), John Camm (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Kenneth Dickstein (Norway), John Lekakis (Greece), Keith McGregor (France), Marco Metra (Italy), João Morais (Portugal), Ady Osterspey (Germany), Juan Tamargo (Spain), José Luis Zamorano (Spain)**

**Document Reviewers, Jaap W. Deckers, CPG Review Coordinator (The Netherlands), Michel Bertrand (France), Bernard Charbonnel (France), Erland Erdmann (Germany), Ele Ferrannini (Italy), Allan Flyvbjerg (Denmark), Helmut Gohlke (Germany), Jose Ramon Gonzalez Juanatey (Spain), Ian Graham (Ireland), Pedro Filipe Monteiro (Portugal), Klaus Parhofer (Germany), Kalevi Pyörälä (Finland), Itamar Raz (Israel), Guntram Schernthaner (Austria), Massimo Volpe (Italy), David Wood (UK)**

### Table of Contents

Preamble . . . . .	C4	Pathophysiology . . . . .	C19
Introduction . . . . .	C4	Treatment to reduce cardiovascular risk . . . . .	C26
Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities . . . . .	C5	Management of CVD . . . . .	C36
Epidemiology of diabetes, IGH, and cardiovascular risk . . . . .	C11	Heart failure and diabetes . . . . .	C45
Identification of subjects at high risk for CVD or diabetes . . . . .	C15	Arrhythmias: AF and sudden death . . . . .	C47
		Peripheral and cerebrovascular disease . . . . .	C50
		Intensive care . . . . .	C54
		Health economics and diabetes . . . . .	C56
		Appendix . . . . .	C58
		References . . . . .	C59

\*Corresponding authors: Lars Rydén, Department of Cardiology, Karolinska University Hospital, Solna SE-171, 76 Stockholm, Sweden. Tel: +46 8 5177 2171; fax: +46 8 31 10 44; Eberhard Standl Department of Endocrinology, Munich Schwabing Hospital, D-80804 Munich, Germany. Tel: +49 89 3068 2523; fax: +49 89 3068 3906. E-mail address: lars.ryden@ki.se; eberhard.standl@lrz.uni-muenchen.de

 The CME Text 'Guidelines on Diabetes, pre-diabetes and cardiovascular diseases' is accredited by the European Board for Accreditation in Cardiology (EBAC) for '2' hours of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/EACCME guidelines, all authors participating in this programme have disclosed potential conflicts of interest that might cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the CME activities.

<sup>†</sup> This is the full text version of Eur Heart J doi:10.1093/eurheartj/ehl260.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.